Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism - Test2 - elhamkhani - TriplyDB

Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism

Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism

http://www.wikidata.org/entity/Q36199008

about

Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis Opposite effects of gene deficiency and pharmacological inhibition of soluble epoxide hydrolase on cardiac fibrosis Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Promising therapies for treatment of nonalcoholic steatohepatitis.Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis.Controversies in the Diagnosis and Management of NAFLD and NASH.Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH)Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation.Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.Pentoxifylline attenuates nitrogen mustard-induced acute lung injury, oxidative stress and inflammation.Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis.Transient receptor potential vanilloid 1 gene deficiency ameliorates hepatic injury in a mouse model of chronic binge alcohol-induced alcoholic liver disease OxNASH score correlates with histologic features and severity of nonalcoholic fatty liver disease.Effects and clinical significance of pentoxifylline on the oxidative stress of rats with diabetic nephropathy.Oxidized metabolites of linoleic acid as biomarkers of liver injury in nonalcoholic steatohepatitis.From NAFLD to Cardiovascular Disease. Is it (Still) the Metabolic Syndrome?Role of pentoxifylline in non-alcoholic fatty liver disease in high-fat diet-induced obesity in mice.Focus on therapeutic strategies of nonalcoholic Fatty liver disease Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.Alcohol produces distinct hepatic lipidome and eicosanoid signature in lean and obese.Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease.Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation KASL clinical practice guidelines: management of nonalcoholic fatty liver disease.Involvement of free radicals and oxidative stress in NAFLD/NASH.Pharmacological agents for NASH.Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities.Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease.Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.Pharmacological agents for nonalcoholic steatohepatitis.Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease.Pharmacotherapy for Nonalcoholic Fatty Liver Disease.The effect of pentoxifylline on L-1 sarcoma tumor growth and angiogenesis in Balb/c mice.The intersection of nonalcoholic fatty liver disease and obesity.Therapies in non-alcoholic steatohepatitis (NASH).

P2860

Q26828765-E05BBAF1-13AE-4D9B-88F3-ABDEA5B38CB5 Q26829503-57BA3D5A-9486-4E53-80DE-186AF3607FDF Q26992163-717CC533-8F7A-4834-8CB5-31E1D54E4E60 Q27007515-803F35BF-999B-4ED4-A06B-B8DAAA17DDC0 Q28084150-C8AC4BEE-B3C6-4FA2-973F-811AB731EFF4 Q28383719-3A1126D0-2E61-4766-B917-BA0E41B7DB6C Q28607750-F9C80732-A20B-40FE-A951-39E4B8391801 Q30248578-FECB2039-916B-4246-91E9-63B8DE070301 Q30377409-03E9C361-9288-420B-9CC1-944CBC2D7FED Q30412296-1ECE906A-306B-4E97-89F1-5BD87478CF3C Q33755566-B9D07DF2-9E45-4DD2-A912-CB51E06DC4FD Q33755829-5DA9385A-FD2C-43B7-A68A-C93B1DDBB197 Q34540703-DC1A8E95-1887-45BB-83E3-18A1C9456FDA Q34647400-9B801AD2-B65D-4F42-AB33-422D6120635F Q34743209-F8ABAEF5-332F-44AC-B976-744CD358B3B2 Q34757421-040932BF-7231-4A87-B1D7-CE231BED727D Q34781469-F0AD882C-E923-48F3-A376-D7BD7B1BE9CA Q34788743-7CC6DE1D-1C51-4C95-9D3E-236FCFC76AA2 Q35662913-71019352-F651-41F0-A2E9-358859FF27FE Q36083096-00088D70-7C0E-435B-9B93-6D8301BDE3F5 Q36207195-F8CB8956-A4C1-4EA9-AD3D-131EC158BAA3 Q36209355-2DA55247-EBCD-479D-A832-53699529AB3A Q36413703-013DD028-D143-4C17-A235-8249654B9F1F Q36818351-C734B399-DE51-4868-888E-4CFAEDA04606 Q36930189-9EEA4A52-2127-4AE5-A008-649A3FBAF48A Q36982040-CFA0885D-DB36-4357-A490-928A75A46DE7 Q37244257-8E6AADB7-9D9C-4787-A644-02AFF6274D0E Q37488800-0AF060B0-BAD9-466E-BC40-6AD466012F5C Q38134169-4C1D6517-1389-488C-804D-28930DD21A74 Q38152646-BF6A16A8-3C7B-40C1-BBCB-A8EC031CB20F Q38160948-7AE00094-78EE-4965-8BB5-9863031F6424 Q38212215-C34807DA-A90F-4EF5-8E1B-D31D60D1BE74 Q38408904-55A442CE-FC37-44B4-9A8C-3BE4DC50560D Q38550285-F3E866E1-9450-4E17-8A90-75DD109263A2 Q38552387-9F24C420-4DE1-4310-8283-E7779A6D0FBC Q38557011-3B3F5C64-C0B0-4E92-9FA5-30A7C014C408 Q38588344-E64495C2-76B1-4E61-B5BC-856492CDEC63 Q38598877-55BFBB1A-F067-4698-B56D-E58DC06C38D3 Q38714560-DC403921-FEF9-4FA6-B150-CEF755C204B8 Q38774861-EFC5288F-489D-4AB8-AB89-87AE548E1C36

P2860

Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism

http://www.wikidata.org/entity/Q36199008

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Pentoxifylline decreases oxidi ...... otential therapeutic mechanism

@ast

Pentoxifylline decreases oxidi ...... otential therapeutic mechanism

@en

type

label

Pentoxifylline decreases oxidi ...... otential therapeutic mechanism

@ast

Pentoxifylline decreases oxidi ...... otential therapeutic mechanism

@en

prefLabel

Pentoxifylline decreases oxidi ...... otential therapeutic mechanism

@ast

Pentoxifylline decreases oxidi ...... otential therapeutic mechanism

@en

P1433

Q36199008-8FEA5C59-CEB4-48A6-8DA0-44EE96FA413E

P1476

Q36199008-810A9267-D735-480C-B9AC-BAA00DD9FC69

P2093

Q36199008-440B1037-512E-4C31-8914-5D7BE21B2BD9

Q36199008-4FDCD263-02BA-4880-A7CF-F169CEE49639

Q36199008-69957E77-10B5-425E-99F1-2E46B8CF5E9E

Q36199008-6ADAA07D-AFAA-4707-A5BC-772378284B45

Q36199008-7CB644AB-2E7E-41AF-8006-1A4891DE2711

Q36199008-81A1E8A9-7CFB-4E95-80E7-51C51BFA4CDD

Q36199008-AEDD190F-E7C8-48E8-8F81-232F5B22E883

Q36199008-F4F4C788-026C-4ACE-986D-DE7942979589

P2860

Q36199008-02860112-5984-4304-85FD-5DED9A949B9D

Q36199008-08F9CFEA-53AE-4CD9-8690-9D8DA324FB42

Q36199008-1DE6D654-4C40-4DC0-8106-9134DB73FD84

Q36199008-2A86EA7E-D263-4083-8672-9DDF7AA8BC8E

Q36199008-34144F6B-71E1-4336-9546-98B350585D55

Q36199008-369424A5-4DBB-45C7-97D2-E20535C247DC

Q36199008-3E3F5BBA-6138-4DBB-8678-F3E8F79C2ADA

Q36199008-4B675FE9-7109-41AC-BE70-C686CCEDB831

Q36199008-4B6C84F5-7FD2-4065-86F4-2705FCB666FF

Q36199008-544FF3FA-546E-4C9A-B728-144326CBF703

P304

Q36199008-272853E6-A8A9-4550-8453-7780BE75D8E2

P31

Q36199008-9D7A3224-A673-4B19-A30E-96BD854968E8

P356

Q36199008-DC7B24D1-9731-429B-AF5C-515F604E5039

P407

Q36199008-D2CB5413-E776-44B3-8C07-F5A35CF5FE6E

P433

Q36199008-B42444D2-1403-4EF8-8FBD-D419790EE5A3

P478

Q36199008-57FBDFA7-B8A8-44A6-9D89-9813C4998615

P577

Q36199008-2B868CBC-7D26-4349-BC36-4C60BFA5AD73

P5875

Q36199008-116C1499-8F8F-4088-BCB7-114350F91E04

P698

Q36199008-C6864354-5781-445D-8B14-C599AD012F53

P921

Q36199008-DD2B641A-86D1-461A-B640-D69D4D812A5B

P932

Q36199008-9F24EB9E-3B6B-47C8-AA5E-E1082239742D

P356

P1433

P1476

Pentoxifylline decreases oxidi ...... otential therapeutic mechanism

@en

P2093

Ariel E Feldstein

http://www.w3.org/2001/XMLSchema#string

Arthur J McCullough

http://www.w3.org/2001/XMLSchema#string

Claudia O Zein

http://www.w3.org/2001/XMLSchema#string

John P Kirwan

http://www.w3.org/2001/XMLSchema#string

Lisa M Yerian

http://www.w3.org/2001/XMLSchema#string

Rocio Lopez

http://www.w3.org/2001/XMLSchema#string

Stanley L Hazen

http://www.w3.org/2001/XMLSchema#string

Xiaoming Fu

http://www.w3.org/2001/XMLSchema#string

P2860

Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis.

Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis

Steatohepatitis: a tale of two "hits"?

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.

Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.

P304

1291-1299

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.25778

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224039048

http://www.w3.org/2001/XMLSchema#string

P698

22505276

http://www.w3.org/2001/XMLSchema#string

P921

Steatohepatitis

P932

3430813

http://www.w3.org/2001/XMLSchema#string